ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2025, Vol. 17 ›› Issue (2): 98-108.doi: 10.20274/j.cnki.issn.1674-3865.2025.02.002

• • 上一篇    下一篇

小儿肺热咳喘口服液治疗肺炎支原体肺炎的Meta分析及GRADE评价

武攀, 黄廷岳, 张占玲, 王雪峰   

  1. 071000 河北 保定，中国中医科学院广安门医院保定医院儿科（武攀，张占玲）；276000 山东 临沂，临沂市妇幼保健院中医科（黄廷岳）；110032 沈阳，辽宁中医药大学附属医院儿科（王雪峰）

  • 收稿日期:2024-09-05 出版日期:2025-04-25 上线日期:2025-04-25
  • 通讯作者: 王雪峰，E-mail：lnzywxf@163.com
  • 基金资助:
    国家中医药管理局小儿肺炎传承创新平台建设项目（2020-1）

Meta analysis and GRADE evaluation of Xiaoer Feire Kechuan oral liquid in the treatment of Mycoplasma pneumoniae pneumonia

WU Pan1，HUANG Tingyue2，ZHANG Zhanling1，WANG Xuefeng3   

  1. 1Baoding Hospital,Guang′anmen Hospital,China Academy of Traditional Chinese Medicine,Baoding 071000,China；2Linyi Maternal and Child Health Hospital，Linyi 276000,China；3Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Shenyang 110032,China
  • Received:2024-09-05 Published:2025-04-25 Online:2025-04-25
  • Contact: WANG Xuefeng，E-mail：lnzywxf@163.com

PDF (PC)

6

摘要： 目的:系统评价小儿肺热咳喘口服液治疗肺炎支原体肺炎的有效性及安全性。方法:计算机检索知网、万方、维普、中国生物医学文献数据库、Pubmed、Cochrane Library、Embase国内外数据库自建库至2024年3月31日所发表的小儿肺热咳喘口服液治疗肺炎支原体肺炎的随机对照试验文献，并追溯相关灰色文献。2名研究者分别独自进行文献筛选与资料提取，并对纳入研究进行质量评价，Meta分析及证据质量评价分别采用RevMan 5-4软件、GRADE系统进行。结果:共纳入16项研究,共1 503例患者,其中试验组752例,对照组751例。Meta分析结果表明，联用小儿肺热咳喘口服液治疗肺炎支原体肺炎的总有效率、热退时间、咳嗽消失时间、咳痰消失时间、肺部啰音消失时间、C反应蛋白水平、白细胞介素6水平、肿瘤坏死因子α水平均优于西医常规治疗，且并未增加不良反应发生率。GRADE证据分级结果显示：总有效率、咳痰消失时间、不良反应发生率的证据级别为低级；热退时间、咳嗽及肺部啰音消失时间、炎性指标(C反应蛋白、白细胞介素6、肿瘤坏死因子α）、肺功能（第一秒用力呼气容积、第一秒用力呼气容积与用力肺活量的比值、最大自主通气量）的证据级别为极低级。结论:小儿肺热咳喘口服液治疗儿童肺炎支原体肺炎疗效确切,安全性优于西医常规治疗。

关键词: 肺炎支原体肺炎, 小儿肺热咳喘口服液, Meta分析, GRADE评价, 儿童

Abstract: Objective:To systematically evaluate the efficacy and safety of Xiaoer Feire Kechuan oral liquid in the treatment of Mycoplasma pneumoniae pneumonia.Methods:Randomized controlled trials of Xiaoer Feire Kechuan oral liquid in the treatment of Mycoplasma pneumoniae pneumonia published in Chinese databases and English databases,including CNKI,Wanfang,VIP,CBM,Pubmed,Cochrane Library and Embase,were searched for by computer and the relevant grey literature was traced.Two researchers conducted literature screening and data extraction separately,and conducted quality evaluation of the included studies.The meta analysis and evidence quality evaluation were carried out using RevMan 5-4 software and GRADE system respectively.Results:A total of 16 studies were included,involving a total of 1 503 patients,752 patients in the experimental group and 751 patients in the control group.The results of meta analysis showed that the total effective rate,the antipyretic time,the disappearance time of cough,the disappearance time of sputum,the disappearance time of lung rales,CRP level,IL6 level and TNFα level were better by Xiaoer Feire Kechuan oral liquid than by conventional western medicine in the treatment of Mycoplasma pneumoniae pneumonia,and the incidence of adverse reactions was not increased.The grading results of GRADE evidence showed that the evidence of total effective rate,the disappearance time of sputum and the incidence of adverse reactions was the low grade;the evidence of antipyretic time,the disappearance time of cough and the disappearance time of lung rales,inflammatory indexes(CRP,IL6,TNFα） and lung function（FEV1,FEV1/FVC,MVV） was the very low grade.Conclusion:The therapeutic effect of Xiaoer Feire Kechuan oral liquid on Mycoplasma pneumoniae pneumonia in children is definite,and its safety is superior to conventional western medicine treatment.

Key words: Mycoplasma pneumoniae pneumonia, Xiaoer Feire Kechuan oral liquid, Meta analysis；GRADE evaluation, Child